AURA
Aura Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.56
+2.58%Aug 11, 2026, 00:00 UTC
Aura Biosciences reported a net loss of $45.6 million for Q2 2026, with diluted EPS of -$0.48, and announced a 20% workforce reduction as part of an organizational realignment, expecting cash runway into the first half of 2029.
Jul 8, 2026, 00:00 UTC
Aura Biosciences appointed Jeremy Bender as a Class II director effective July 7, 2026.